Eye Clinic, Polytechnic University of Marche, Ancona, Italy.
Private practice, Area Vasta 2, Fabriano, Italy.
Eur J Ophthalmol. 2023 Jul;33(4):NP46-NP50. doi: 10.1177/11206721221118736. Epub 2022 Aug 11.
We report two cases of optic neuritis following Pfizer-BioNTech COVID-19 vaccination in patients with autoimmune diseases. Post-vaccine optic neuritis, although rare, is reported in the literature and an autoimmune mechanism seems to be involved, especially in genetically predisposed subjects.
Report of two cases of optic neuritis following COVID-19 vaccination in patients with autoimmune diseases.
He novelty of this article is the fact that the two patients had a medical history of autoimmune diseases (Hashimoto thyroiditis and ankylosing spondylitis), a point of interest for research because it is not yet clear whether this could constitute a risk factor for adverse events after vaccination.
The reactogenicity of COVID-19 mRNA vaccine in individuals suffering from immune-mediated diseases is yet to be elucidated and it is being increasingly investigated. Our paper supports the hypothesis that patients who are already affected or predisposed to autoimmune or autoinflammatory disorders should be carefully evaluated for the benefits and risks of COVID-19 mRNA vaccination.
我们报告了两例自身免疫性疾病患者在接种辉瑞-生物科技公司的 COVID-19 疫苗后发生视神经炎的病例。疫苗接种后发生视神经炎虽然罕见，但已有文献报道，并且似乎涉及自身免疫机制，特别是在具有遗传易感性的患者中。
报告两例自身免疫性疾病患者在接种 COVID-19 疫苗后发生视神经炎的病例。
本文的新颖之处在于这两名患者均有自身免疫性疾病（桥本甲状腺炎和强直性脊柱炎）病史，这一点值得研究，因为目前尚不清楚这是否构成疫苗接种后不良事件的危险因素。
免疫介导性疾病患者对 COVID-19 mRNA 疫苗的反应性尚不清楚，目前正在进行越来越多的研究。我们的论文支持这样一种假设，即已经患有自身免疫或自身炎症性疾病或易患此类疾病的患者，应仔细评估 COVID-19 mRNA 疫苗接种的获益和风险。
